Use of short-acting insulin aspart in managing older people with diabetes

Review

(2758) Views  (669) Full article downloads

Authors: Eltayeb Marouf, Alan J Sinclair

Published Date April 2009 Volume 2009:4 Pages 187 - 190

DOI: http://dx.doi.org/10.2147/CIA.S3142

Eltayeb Marouf, Alan J Sinclair

Institute of Diabetes for Older People – IDOP, Bedfordshire and Hertfordshire Postgraduate Medical School, University of Bedfordshire, UK

Abstract: Type 2 diabetes mellitus affects 5.9% of the world adult population, with older people and some ethnic groups disproportionately affected. Treatment of older people with diabetes differs in many ways from that in younger adults since the majority have type 2 disease and are at particular risk of macrovascular rather than disabling microvascular disease. Insulin therapy, the most effective of diabetes medications, can reduce any level of elevated HBA1c if used in adequate doses. However, some clinicians are often reluctant to initiate insulin therapy in older people with diabetes mainly out of their concerns about adverse reactions to insulin, particularly hypoglycemia. There is evidence suggesting that insulin aspart appears to act similarly to regular human insulin in older people with type 2 diabetes mellitus. Insulin aspart can be used in the treatment of older people with diabetes, but this should be individualized. There is evidence that it improves postprandial glucose control, improves long-term metabolic control, reduces risk of major nocturnal hypoglycemia and increases patient satisfaction compared with soluble insulin.

Keywords: older people, diabetes, insulin aspart, hypoglycemia